"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (CD28 ANTIGENS) and CD80 antigens (B7-1 ANTIGEN).
| Descriptor ID |
D019139
|
| MeSH Number(s) |
G12.900
|
| Concept/Terms |
Tumor Escape- Tumor Escape
- Tumor Immune Evasion
- Evasion, Tumor Immune
- Evasions, Tumor Immune
- Immune Evasions, Tumor
- Tumor Immune Evasions
- Immune Evasion, Tumor
- Immune Escape, Tumor
- Tumor Immune Escape
|
Below are MeSH descriptors whose meaning is more general than "Tumor Escape".
Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".
This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Escape" by people in Profiles.
-
Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 12; 161(6):1813-1829.
-
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer. Oncogene. 2021 10; 40(41):5984-5992.
-
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends Cancer. 2019 04; 5(4):208-232.
-
Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. 2018 03; 154(4):1024-1036.e9.
-
Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-? signaling. J Clin Invest. 2017 Apr 03; 127(4):1321-1337.
-
Surface Expression of TGF? Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. Cancer Res. 2016 12 15; 76(24):7106-7117.
-
The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression. Trends Mol Med. 2016 Jan; 22(1):1-3.
-
Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype. J Hematol Oncol. 2015 02 20; 8:13.
-
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumors. J Immunol. 2015 Feb 15; 194(4):1434-45.
-
Novel immunotherapies for hematologic malignancies. Immunol Rev. 2015 Jan; 263(1):90-105.